Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03909334
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- NCT03909334 ↗
- Active, not recruiting
- Xiuning Le
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03909334 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03909334 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X |
The trial
ClinicalTrials.gov- Official title
- An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer; EGFR Gene Mutation; Advanced Cancer; Metastatic Cancer
- Interventions
- Osimertinib; Ramucirumab
- Arms
- Arm A (Osimertinib and Ramucirumab) · Active comparator
- Arm B (Osimertinib) · Active comparator
- Enrollment
- 160
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Xiuning Le with M.D. Anderson Cancer Center, Eli Lilly and Company
- Start
- Jul 25, 2019
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03909334 · updated Apr 17, 2026
Publications
linked from the registry- Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8. PubMed 39378386